ArticleAdvances in cancer research2022
Nephrotoxicity in cancer treatment: An update.
Article in Advances in cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Naringenin Attenuates Methotrexate-Induced Nephrotoxicity Accompanied by Alterations in Oxidative Stress, Inflammatory, Apoptotic, and Endoplasmic Reticulum Stress Responses.International journal of molecular sciences · 2026Article
- Comparison of survival outcomes between kidney transplant and dialysis in patients with previous cancer.Chinese medical journal · 2026Observational
- Iodinated Contrast Media in Oncologic CT: A Narrative Review of Safety, Risk Stratification, and Practical Considerations.Diagnostics (Basel, Switzerland) · 2026Review
- Octahedral [(8-quinolinyl/phenanthridinyl)amine)Ga(III)] complexes, reactivity, affinity for biomolecules, anti-cancer and computational evaluations.Reaction kinetics, mechanisms and catalysis · 2026Article
- Association of urinary sodium and potassium excretion with outcomes of neuroendocrine cancer.Frontiers in oncology · 2026Article
- GRK2 dysfunction mediates acute kidney injury in murine administered methotrexate combined with omeprazole.Acta pharmacologica Sinica · 2026Article
- Incidence of renal injury following chemotherapy in malignant tumor patients and analysis of associated factors.Frontiers in medicine · 2026Article
- Riociguat Alleviates Cisplatin-Caused Kidney Injury by Suppressing Oxidative Stress and Inflammation.Biology · 2025Article
- Preclinical evaluation of sodium copper chlorophyllin: safety, pharmacokinetics, and therapeutic potential in breast cancer chemotherapy and cyclophosphamide-induced bladder toxicity.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Review
- Mitigation of cisplatin-induced acute kidney injury through oral administration of fatty acid amide hydrolase inhibitor PF-04457845.The Journal of pharmacology and experimental therapeutics · 2025Article
- Systemic Toxicity Profile of Chemotherapeutic Agents in a Wistar Rat Model: A Preliminary Report.Journal of toxicology · 2025Article
- Effects of Dulaglutide in Doxorubicin Induced Renal Toxicity in Rats.Biologics : targets & therapy · 2025Article
- Article
- Chemotherapy impairs ovarian function through excessive ROS-induced ferroptosis.Cell death & disease · 2023Article
- Genetic Knockout of Fatty Acid Amide Hydrolase Ameliorates Cisplatin-Induced Nephropathy in Mice.Molecular pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
It has been estimated that nearly 80% of anticancer drug-treated patients receive potentially nephrotoxic drugs, while the kidneys play a central role in the excretion of anticancer drugs. Nephrotoxicity has long been a serious complication that hampers the effectiveness of cancer treatment and continues to influence both mortality and length of hospitalization among cancer patients exposed to either conventional cytotoxic agents or targeted therapies. Kidney injury arising from anticancer drugs tends to be associated with preexisting comorbidities, advanced cancer stage, and the use of concomitant non-chemotherapeutic nephrotoxic drugs. Despite the prevalence and impact of kidney injury on therapeutic outcomes, the field is sorely lacking in an understanding of the mechanisms driving cancer drug-induced renal pathophysiology, resulting in quite limited and largely ineffective management of anticancer drug-induced nephrotoxicity. Consequently, there is a clear imperative for understanding the basis for nephrotoxic manifestations of anticancer agents for the successful management of kidney injury by these drugs. This article provides an overview of current preclinical research on the nephrotoxicity of cancer treatments and highlights prospective approaches to mitigate cancer therapy-related renal toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.